Evolving pituitary abnormalities in a child with newly diagnosed ROHHAD syndrome
DOI:
https://doi.org/10.18203/2349-3291.ijcp20261142Keywords:
ROHHAD, Rapid-onset obesity, Hypothalamic dysfunction, Pituitary bright spot loss, Diabetes insipidus, Central hypothyroidism, Central sleep apneaAbstract
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD) is a rare pediatric disease with a high rate of morbidity and mortality. Most reported cases of ROHHAD demonstrate normal magnetic resonance imaging (MRI) findings despite hypothalamic-pituitary abnormalities; only a few describe interval structural changes. We describe a 17-month-old female with rapid-onset obesity, central hypothyroidism, and developmental delay who presented with polyuria and irritability. Laboratory evaluation confirmed central diabetes insipidus, and repeat MRI revealed loss of the posterior pituitary bright spot compared to a normal study five months earlier. She was treated with desmopressin and did not demonstrate any additional pituitary dysfunction. This case supports the need for close monitoring and follow up in children with suspicion of ROHHAD, as the clinical course has the potential to evolve quickly. Repeat imaging and hormonal evaluation are key in the early detection and management of disease progression. The evolving pituitary findings also suggest a possible autoimmune etiology of ROHHAD warranting further research into its pathogenesis and the need for biomarkers to assess disease progression.
References
Lee YA, Cho JH, Seo JH, Ahn SY, Lee JE, Rhie YJ, et al. Clinical Presentation and Course of ROHHAD Syndrome: A Systematic Review. Ann Pediatr Endocrinol Metab. 2023;28(3):129-37
Bougnerès P, Bordes S, Jean-Baptiste S, Roland MA, Tauber M, Doray B, et al. Endocrine Manifestations in Children with ROHHAD/ROHHAD-NET Syndrome. J Clin Endocrinol Metab. 2008;93(10):4155-61.
Hawton K, Smith L, Brown R, Jones C, Patel M, Davies M, et al. Neuroendocrine Tumours in ROHHAD-NET: Clinical and Imaging Features in a Case Series. Horm Res Paediatr. 2023;96(5):347-55.
Kim H, Zhang X, Park SJ, Lee SM, Xu Q, Lee JH, et al. Rapid Progression of ROHHAD with Anti-ZSCAN1 Antibody: A Case Report. Ann Pediatr Endocrinol Metab. 2024;29(1):45-52.
van Engelen N, van Santen HM, van Dijk F, Kleisman MM, Merks JHM, Schouten-van Meeteren AYN, et al. Genetic evaluation of five patients with ROHHAD-NET using whole genome sequencing and optical genome mapping. Orphanet J Rare Dis. 2025;20(1):412.
Sethi P, Sankar T, Smith J, Haldeman-Englert C, Witherspoon K, DePetris R, et al. Whole genome sequencing in ROHHAD trios proved inconclusive: what’s beyond? Am J Med Genet A. 2023;191(10):2395-403.
Giacomozzi C, Guaraldi F, Cambiaso P, Niceta M, Verrillo E, Tartaglia M, et al. Anti-hypothalamus and anti-pituitary auto-antibodies in ROHHAD syndrome: Additional evidence supporting an autoimmune etiopathogenesis. Horm Res Paediatr. 2019;92(2):124-32.
Mandel-Brehm C, Benson LA, Tran B, Kung AF, Mann SA, Vazquez SE, et al. ZSCAN1 Autoantibodies Are Associated with Pediatric Paraneoplastic ROHHAD. Ann Neurol. 2022;92(2):279-91.
Tocan V, Nakamura-Utsunomiya A, Sonoda Y, Matsuoka W, Mizuguchi S, Muto Y, et al. High-Titer Anti-ZSCAN1 Antibodies in a Toddler Clinically Diagnosed with Apparent Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome. Int J Mol Sci. 2024;25(5):2820.